M Freuding1, C Keinki1, S Kutschan1, O Micke2, J Buentzel3, Jutta Huebner4. 1. Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. 2. Klinik für Strahlentherapie und Radioonkologie, Franziskus Hospital, Kiskerstraße 26, 33615, Bielefeld, Germany. 3. Klinik für Hals-Nasen-Ohren-Heilkunde, Südharzklinikum Nordhausen, Dr.-Robert-Koch-Straße 39, 99734, Nordhausen, Germany. 4. Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. jutta.huebner@med.uni-jena.de.
Abstract
PURPOSE: One important goal of any cancer therapy is to improve or maintain quality of life. In this context, mistletoe treatment is discussed to be highly controversial. The aim of this systematic review is to give an extensive overview about the current state of evidence concerning mistletoe therapy of oncologic patients regarding quality of life and side effects of cancer treatments. METHODS: In September and October 2017, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and "Science Citation Index Expanded" (Web of Science) were systematically searched. RESULTS: The search strategy identified 3647 articles and 28 publications with 2639 patients were finally included in this review. Mistletoe was used in bladder cancer, breast cancer, other gynecological cancers (cervical cancer, corpus uteri cancer, and ovarian cancer), colorectal cancer, other gastrointestinal cancer (gastric cancer and pancreatic cancer), glioma, head and neck cancer, lung cancer, melanoma and osteosarcoma. In nearly all studies, mistletoe was added to a conventional therapy. Regarding quality of life, 17 publications reported results. Studies with better methodological quality show less or no effects on quality of life. CONCLUSIONS: With respect to quality of life or reduction of treatment-associated side effects, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer.
PURPOSE: One important goal of any cancer therapy is to improve or maintain quality of life. In this context, mistletoe treatment is discussed to be highly controversial. The aim of this systematic review is to give an extensive overview about the current state of evidence concerning mistletoe therapy of oncologic patients regarding quality of life and side effects of cancer treatments. METHODS: In September and October 2017, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, CINAHL and "Science Citation Index Expanded" (Web of Science) were systematically searched. RESULTS: The search strategy identified 3647 articles and 28 publications with 2639 patients were finally included in this review. Mistletoe was used in bladder cancer, breast cancer, other gynecological cancers (cervical cancer, corpus uteri cancer, and ovarian cancer), colorectal cancer, other gastrointestinal cancer (gastric cancer and pancreatic cancer), glioma, head and neck cancer, lung cancer, melanoma and osteosarcoma. In nearly all studies, mistletoe was added to a conventional therapy. Regarding quality of life, 17 publications reported results. Studies with better methodological quality show less or no effects on quality of life. CONCLUSIONS: With respect to quality of life or reduction of treatment-associated side effects, a thorough review of the literature does not provide any indication to prescribe mistletoe to patients with cancer.
Entities:
Keywords:
Cancer; Complementary and alternative medicine (CAM); Mistletoe; Patient-relevant outcomes
Authors: Jutta Hübner; Matthias Beckmann; Markus Follmann; Monika Nothacker; Franz Josef Prott; Bernhard Wörmann Journal: Dtsch Arztebl Int Date: 2021-10-01 Impact factor: 8.251
Authors: Emanuelle do Nascimento Santos Lima; Isabela Borges Ferreira; Paula Philbert Lajolo; Carlos Eduardo Paiva; Yara Cristina de Paiva Maia; Geórgia das Graças Pena Journal: Health Qual Life Outcomes Date: 2020-09-16 Impact factor: 3.186
Authors: Harald Matthes; Anja Thronicke; Ralf-Dieter Hofheinz; Erik Baars; David Martin; Roman Huber; Thomas Breitkreuz; Gil Bar-Sela; Daniel Galun; Friedemann Schad Journal: Evid Based Complement Alternat Med Date: 2020-02-18 Impact factor: 2.629
Authors: Massimiliano Berretta; Luca Rinaldi; Rosaria Taibi; Paolo Tralongo; Alberto Fulvi; Vincenzo Montesarchio; Giordano Madeddu; Paolo Magistri; Sabrina Bimonte; Marco Trovò; Patrizia Gnagnarella; Arturo Cuomo; Marco Cascella; Arben Lleshi; Guglielmo Nasti; Sergio Facchini; Francesco Fiorica; Raffaele Di Francia; Giuseppe Nunnari; Giovanni Francesco Pellicanò; Aurelio Guglielmino; Marco Danova; Sabrina Rossetti; Alfonso Amore; Anna Crispo; Gaetano Facchini Journal: Front Oncol Date: 2020-04-28 Impact factor: 6.244